News and Announcements
SUDA Investor Presentation May 2016
- Published May 03, 2016 4:42PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
3rd May 2016, ASX Announcement
Overview
SUDA (ASX: SUD) is a drug delivery company commercialising low-risk pharmaceuticals
Extensive proprietary technology, expertise and knowhow in formulating and manufacturing oral sprays
Multiple patent families covering approx. 300 widely-used drugs formulated into oral sprays
SUDA’s first-in-class oral sprays have demonstrated meaningful advantages vs. standard-of-care tablets in multiple clinical studies
Multiple oral sprays for large markets – insomnia, malaria, migraine, erectile dysfunction, chemo-induced nausea
Technology proven with 3 products on the market: NitroMist (Nitro-Glycerine), ZolpiMist and Meloxicam (Vet)
To view the presentation please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
